Press

Iter Investments Announces the Closing of First Fund

Jul 15 • 4 min read

FORT LAUDERDALE, Fla., July 14, 2022 /PRNewswire/ — Iter Investments, a venture capital firm that aims to deploy capital primarily in businesses operating in and around the burgeoning psychedelic industry, is pleased to announce the final closing of its successful round of funding on June 15. When Iter Investments first launched the initial fund in April 2021, it targeted a $20…

Albert Labs Files US Provisional Patent Application for Psilocybe And Other Mycelia

Jul 13 • 3 min read

Albert Labs International Corp. (CSE: ABRT | FSE: VB50), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines, based on mycelia of Psilocybe and other fungi, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a proprietary process. Albert Labs’ culturing process can…

Filament Health Issued Third Patent by United States Patent and Trademark Office

Jul 13 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a third patent by the United States Patent and Trademark Office for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming…

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Jul 12 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (“CKD”) research program with NP-251 (“Repirinast”). In Q1 2022, the Company announced that it had initiated a new CKD research program to investigate Repirinast as part of…

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Jul 11 • 3 min read

-Cybin Inc. (NEO: CYBN | NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a Phase 1 N,N-dimethyltryptamine study from Entheon Biomedical Corp. (CSE: ENBI | OTCQB: ENTBF | FSE: 1XU1). This DMT study, which is the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435